Long acting GLP-1 receptor agonist (injectable)
Ecnoglutide injection
ECNO_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.45 (-2.41 to -0.42) | 0.79 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -2.05 (-6.86 to 3.10) | 0.61 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.56 (0.07 to 62.96) | 0.41 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.56 (0.07 to 62.14) | 0.47 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.03 (0.79 to 37.67) | 0.27 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.71 (0.28 to 107) | 0.35 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.89 (1.06 to 43.58) | 0.14 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.34 (0.33 to 8.30) | 0.47 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.66 (0.04 to 11.40) | 0.45 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.38 (0.00 to 29.91) | 0.68 |